NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
More news: Research
Written by / Agency / Source: Frost & Sullivan
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

WuXi AppTec Applauded by Frost & Sullivan for its Unmatched Breadth of Expertise in Facilitating Early-stage Innovation and Clinical Research - The company accelerated clients' R&D and ensured agility by leveraging a global footprint, keen customer focus, and customized solutions - WuXiAppTec.com / Frost.com
WuXi AppTec Applauded by Frost & Sullivan for its Unmatched Breadth of Expertise in Facilitating Early-stage Innovation and Clinical Research

 

NewswireToday - /newswire/ - London, United Kingdom, 2020/12/03 - The company accelerated clients' R&D and ensured agility by leveraging a global footprint, keen customer focus, and customized solutions - WuXiAppTec.com / Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the global contract research organization (CRO) market, Frost & Sullivan recognizes WuXi AppTec with the 2020 Global Customer Value Leadership Award. WuXi AppTec offers end-to-end services in R&D and manufacturing that enable companies in the pharmaceutical, biotech, and medical device industries to advance discoveries and deliver innovative treatments. It has been expanding its industry-leading services rapidly, with a particular focus on contract development and manufacturing for small molecules, peptides, oligonucleotides, and cell and gene therapies (CGT).

Even as COVID-19 continues to pose a risk to ongoing clinical trials and new trials’ initiation, WuXi AppTec has ensured business continuity for its partners by adopting virtual trial protocols and shifting workloads between sites. Its efforts also include building new scientific capabilities, such as developing a set of in vitro biology assays against various novel drug targets of COVID-19 at record speed. This has helped the company expeditiously deliver preclinical testing packages for potential COVID-19 treatments. Furthermore, the company worked with regulatory officials, healthcare professionals, and advisors to plan and execute new guidelines on remote monitoring and virtual trials through its subsidiary, WuXi Clinical.

“WuXi AppTec’s differentiated customer service approach emphasizes understanding the different needs of its customers and accordingly curating customized packages,” said Deepak Jayakumar, Industry Analyst. “Instead of presenting clients with an unnecessary comprehensive package, it offers client-specific and feature-integrated services or bundles. The customized packages enable rapid testing and turnaround of experiments and scientific hypotheses through access to the company’s advanced technologies. The company has also custom-built systems and processes within several business functions to improve real-time project tracking.”

Meanwhile, WuXi AppTec’s range of service offerings to support the development of CGT includes process development and manufacturing services, integrated testing and analytical development services, and manufacturing support. With process development, manufacturing, and testing facilities on two continents, with the capacity and capability to support customers globally, WuXi AppTec can help customers access all major markets.

“WuXi AppTec has strived to identify populations with the greatest clinical trial potential while advancing trials that incorporate local best practices and expertise,” noted Jayakumar. “Robust demand, an increase in capacity utilization, and efficient operations, along with its focus on providing best-in-class services, have helped WuXi AppTec garner significant business opportunities across different stages of the drug development process.”

Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in implementing strategies that proactively create value for its customers with a focus on improving the return on the investment that customers make in its services or products. The award recognizes the company’s unique focus on augmenting the value that its customers receive, beyond simply good customer service, leading to improved customer retention and customer base expansion.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Frost & Sullivan

For six decades, Frost & Sullivan (frost.com) has been world-renowned for its role in helping investors, corporate leaders, and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models, and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

About WuXi AppTec

WuXi AppTec (wuxiapptec.com) provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions and has received ESG (Environment, Social and Governance) A Ratings from Morgan Stanley Capital International’s since 2019. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need and to realize our vision that “every drug can be made and every disease can be treated.”

Contact: Gracie Rong
P: +86 2138709479 - E: E: Mediainquiries[.]wuxiapptec.com.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Research Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Research articles,
CATCH Visitors via Your Competitors Announcements!


WuXi AppTec Applauded by Frost & Sullivan for its Unmatched Breadth of Expertise in Facilitating Early-stage Innovation and Clinical Research

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Kristen Moore - Frost.com 
210-247-3823 kristen.moore[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Research via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Research Most Recent Related Newswires:

Precision NanoSystems joins Danaher’s Life Sciences Platform
Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities
ABB and ETH Extend Partnership to Advance Research into the Future of Robotics
Naval Group Partners with Flinders University on Exoskeleton Research
Leonardo Contributes to the Innovation of the Sardinia Radio Telescope in Sardinia
Bruker Establishes New Customer Support Center in the Middle East At King Abdullah University of Science and Technology Research Park
ABB and Talga to Explore Development and Construction Options for Major European Battery Anode Project
ABB Strengthens Research into Smart Materials with New R&D Facility
DSM Completes Acquisition of Erber Group
PPG Announces Partnership with Bradford Science Festival to Support Next-generation STEM Workforce
Peking University and Thales Sign A Contract to Develop A Very High Peak Power Laser System in China
University of Antwerp and Imec Launch Crowdscan - A New Spin-off to Measure Crowds without Compromising Personal Privacy
BASF Supports Search for Active Ingredients to Combat Coronavirus SARS-CoV-2
Bruker Corporation Announces Successful Installation of World’s First 1.2 GHz NMR System Enables Novel Functional Structural Biology Research
Innovation Platform Nexplore Forms Research Cooperation with TU Darmstadt

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  BizJobs.com





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)